Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins and acquisitions, here’s a quick look at which stocks will be ...
AstraZeneca is investing in the broadest and ... For example, by building on the success of Forxiga (dapagliflozin), the first SGLT2 inhibitor to demonstrate a mortality benefit in chronic kidney ...
As the vaccine module of the Covid Inquiry gets underway, The Telegraph’s Investigations team explores the link between the AstraZeneca jab and a potentially deadly reaction. We hear from the ...
AstraZeneca says a strong 2024 and stacked pipeline spells potential for further growth in 2025 as the company aims to bring in $80bn in revenue by 2030. CFO Aradhana Sarin outlined AstraZeneca ...
AstraZeneca CFO Aradhana Sarin promised Phase III readouts and revenue growth in 2025 despite ongoing investigations of its Chinese operations. Credit: Bloomberg/ Getty Images AstraZeneca says a ...
If the EMA follows the CHMP’s advice, Zynquista will become the second SGLT-acting drug to be approved for use alongside insulin in type 1 diabetes after AstraZeneca’s SGLT2 inhibitor Forxiga ...
Genome engineering business Synthego will have access to AstraZeneca’s CRISPR gene editing enzyme in its second licensing agreement in the past year.
AstraZeneca plc, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca was formed on Apr 6, 1999, through the merger of Sweden’s Astra AB and ...
It’s now official: Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against AstraZeneca’s standard-of-care Tagrisso as a first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback